BRPI0720546A2 - Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto - Google Patents

Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto

Info

Publication number
BRPI0720546A2
BRPI0720546A2 BRPI0720546-5A BRPI0720546A BRPI0720546A2 BR PI0720546 A2 BRPI0720546 A2 BR PI0720546A2 BR PI0720546 A BRPI0720546 A BR PI0720546A BR PI0720546 A2 BRPI0720546 A2 BR PI0720546A2
Authority
BR
Brazil
Prior art keywords
compound
inhibitor
drug
pharmaceutical composition
treating cancer
Prior art date
Application number
BRPI0720546-5A
Other languages
English (en)
Inventor
Haruko Kawato
Masaki Miyazaki
Yuuichi Sugimoto
Hiroyuki Naito
Tooru Okayama
Tsunehiko Soga
Kouichi Uoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0720546A2 publication Critical patent/BRPI0720546A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0720546-5A 2006-12-14 2007-12-12 Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto BRPI0720546A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006336662 2006-12-14
PCT/JP2007/073930 WO2008072655A1 (ja) 2006-12-14 2007-12-12 イミダゾチアゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0720546A2 true BRPI0720546A2 (pt) 2015-06-23

Family

ID=39511672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720546-5A BRPI0720546A2 (pt) 2006-12-14 2007-12-12 Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto

Country Status (11)

Country Link
US (1) US20090312310A1 (pt)
EP (1) EP2103619A4 (pt)
JP (1) JPWO2008072655A1 (pt)
KR (1) KR20090090383A (pt)
CN (1) CN101605798A (pt)
AU (1) AU2007332493A1 (pt)
BR (1) BRPI0720546A2 (pt)
CA (1) CA2672565A1 (pt)
MX (1) MX2009006397A (pt)
TW (1) TW200831518A (pt)
WO (1) WO2008072655A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JPWO2009151069A1 (ja) * 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
JP2011037819A (ja) * 2008-11-21 2011-02-24 Tosoh Corp ヒドロキシアルキルトリエチレンジアミン類の製造方法
ES2463820T3 (es) 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Derivado de imidazotiazol que tiene estructura de anillo de prolina
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013080141A1 (en) * 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US11332479B2 (en) 2016-07-05 2022-05-17 Korea Institute Of Science And Technology Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
KR101948805B1 (ko) * 2016-07-05 2019-02-15 한국과학기술연구원 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
BR112021006647A2 (pt) 2018-10-08 2021-07-13 The Regents Of The University Of Michigan degradores de proteína mdm2 de pequenas moléculas
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271480A (en) * 1985-04-22 1990-07-10 Toyo Jozo Co., Ltd. 5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives or salts thereof
JP3670309B2 (ja) * 1993-04-01 2005-07-13 第一製薬株式会社 二環性複素環化合物
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
EP1143943B1 (en) * 1999-01-29 2007-12-12 The Board Of Trustees Of The University Of Illinois USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
JP2002105085A (ja) * 2000-09-28 2002-04-10 Yamanouchi Pharmaceut Co Ltd 新規イミダゾチアゾール誘導体
CN1596114A (zh) 2001-11-13 2005-03-16 三维药物公司 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
US20060189511A1 (en) 2002-05-13 2006-08-24 Koblish Holly K Method for cytoprotection through mdm2 and hdm2 inhibition
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US20040197893A1 (en) 2002-10-16 2004-10-07 Carsten Schubert HDM2-inhibitor complexes and uses thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
EA200501513A1 (ru) 2003-04-25 2006-06-30 Орто-Макнейл Фармасьютикал, Инк. Замещённые 1, 4 - диазепины и их применения
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
MXPA05013465A (es) 2003-06-17 2006-03-09 Hoffmann La Roche Cis-imidazolinas como inhibidores de mdm2.
WO2005003097A1 (en) 2003-06-17 2005-01-13 F. Hoffmann-La Roche Ag Cis-2,4,5-triaryl-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
KR101139263B1 (ko) 2005-03-16 2012-05-16 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의그의 용도

Also Published As

Publication number Publication date
TW200831518A (en) 2008-08-01
KR20090090383A (ko) 2009-08-25
EP2103619A1 (en) 2009-09-23
US20090312310A1 (en) 2009-12-17
JPWO2008072655A1 (ja) 2010-04-02
CA2672565A1 (en) 2008-06-19
MX2009006397A (es) 2009-08-13
WO2008072655A1 (ja) 2008-06-19
CN101605798A (zh) 2009-12-16
EP2103619A4 (en) 2011-11-23
AU2007332493A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BR112013023175A2 (pt) composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI1007334A2 (pt) composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer.
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0821209A2 (pt) composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0720169A2 (pt) Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0815360A2 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.